R&D Insights: How MannKind Corporation and Taro Pharmaceutical Industries Ltd. Allocate Funds

Comparing R&D strategies of MannKind and Taro Pharmaceutical.

__timestampMannKind CorporationTaro Pharmaceutical Industries Ltd.
Wednesday, January 1, 201410024400055430000
Thursday, January 1, 20152967400065510000
Friday, January 1, 20161491700071160000
Sunday, January 1, 20171411800070644000
Monday, January 1, 2018873700070418000
Tuesday, January 1, 2019690000063238000
Wednesday, January 1, 2020624800059777000
Friday, January 1, 20211231200060152000
Saturday, January 1, 20221972100054540000
Sunday, January 1, 20233128300052243000
Monday, January 1, 202464536000
Loading chart...

Cracking the code

R&D Spending: A Tale of Two Pharmaceutical Giants

In the competitive world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. MannKind Corporation and Taro Pharmaceutical Industries Ltd. have taken distinct paths in their R&D investments over the past decade. From 2014 to 2023, MannKind's R&D spending saw a dramatic decline of nearly 70%, from its peak in 2014 to its lowest in 2020. However, a resurgence is evident with a 400% increase by 2023. In contrast, Taro Pharmaceutical maintained a steady R&D investment, averaging around $63 million annually, with minor fluctuations. This consistent approach underscores Taro's commitment to sustained innovation. The data for 2024 is incomplete, highlighting the dynamic nature of financial reporting. As these companies navigate the future, their R&D strategies will be pivotal in shaping their competitive edge and market leadership.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025